4-(2,3-dimethoxy-phenyl)-4-piperidinylmethanone trifluoroacetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(2,3-dimethoxy-phenyl)-4-piperidinylmethanone trifluoroacetate
• 英文别名: 4-(2,3-dimethoxyphenyl)-4-piperidinylmethanone trifluoroacetate；4-(2,3-dimethoxyphenyl)piperidine-4-carbaldehyde;2,2,2-trifluoroacetic acid
• 化学式: C₂HF₃O₂*C₁₄H₁₉NO₃
• 分子量: 363.334
• InChiKey: FJBKIMJIMHITKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.16
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-(2,3-dimethoxy-phenyl)-4-piperidinylmethanone trifluoroacetate 、 sodium hydroxide 在 二氯甲烷 、 Brine 、 magnesium sulfate 作用下， 以 水 为溶剂， 以to afford 4-(2,3-dimethoxyphenyl)4-piperidinylmethanone as an oil的产率得到4-(2,3-Dimethoxyphenyl)-4-piperidinylmethanone
  参考文献：
  名称：

  Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of behavioral or psychological symptoms associated with a disease

  摘要：

  本发明涉及使用(+)-α-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇或其预药物，其公式为II，其中R为C1-20烷基，用于治疗与阿尔茨海默病、路易体痴呆或帕金森病相关的行为或心理症状的患者。

  公开号：

  US07132433B2
• 作为产物：
  描述：

  N-叔丁氧羰基-(2,3-二甲氧基苯基)-4-哌啶基甲酮 以 三氟乙酸 为溶剂， 生成 4-(2,3-dimethoxy-phenyl)-4-piperidinylmethanone trifluoroacetate
  参考文献：
  名称：

  (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[

  摘要：

  本发明涉及一种新的5HT.sub.2拮抗剂，(+)-.alpha.-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇，以及其在治疗多种疾病状态中的应用。

  公开号：

  US05134149A1

文献信息

• Use of
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US06022877A1

  公开（公告）日：2000-02-08

  The present invention is directed to the use of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol in treating Depressive Disorders and Bipolar Disorders.

  本发明涉及使用(+)-α-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇治疗抑郁症和躁郁症。
• Treatment of obsessive-compulsive disorders with 5-HT.sub.2 antagonists
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US05618824A1

  公开（公告）日：1997-04-08

  The present invention is directed to 5-HT.sub.2 antagonists and their use as agents in the treatment of obsessive-compulsive disorders (OCD). The invention is particularly directed to the compound (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol which is a member of a class of 5-HT.sub.2 antagonists known as N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5-HT.sub.2 receptor site.

  本发明涉及5-HT.sub.2拮抗剂及其作为治疗强迫症障碍（OCD）的药物的用途。本发明特别涉及化合物(+)-.alpha.-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇，它是一类称为N-芳基哌啶甲醇衍生物的5-HT.sub.2拮抗剂的成员，这些拮抗剂是5-HT.sub.2受体位点上对5-羟色胺结合具有强效和选择性抑制作用的物质。
• COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF
  申请人：EMMONS Gary T.

  公开号：US20080139615A1

  公开（公告）日：2008-06-12

  The invention concerns the combination of a short-acting hypnotic agent and R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (Compound A) or its prodrug having the Formula II: wherein R is C 1 -C 20 alkyl or a pharmaceutically acceptable salt thereof. The combination of this invention is useful in treating a variety of sleep disorders.

  该发明涉及短效催眠药剂和R-(+)-α-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇（化合物A）或其具有II式的前药：其中R为C1-C20烷基或其药用可接受的盐。该发明的组合物在治疗各种睡眠障碍方面是有用的。
• Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US06028083A1

  公开（公告）日：2000-02-22

  The present invention is directed to esters of (+)-.alpha.-(2,3 Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, pharmaceutical formulations, methods of making and methods of using these esters. These compounds antagonize the effects of serotonin at the 5HT.sub.2A receptor and are useful in treating various conditions such as, for example, psychoses such as schizophrenia.

  本发明涉及(+)-α-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇的酯类化合物、药物配方、制备方法和使用方法。这些化合物在5HT.sub.2A受体上拮抗5-羟色胺的作用，可用于治疗各种疾病，例如精神分裂症等精神病。
• Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
  申请人：——

  公开号：US20020099076A1

  公开（公告）日：2002-07-25

  The present invention is directed to use of (+)-&agr;-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or its prodrug (Formula II) in treating patients for symptoms of dementia and dopamine induced psychosis. 1

  本发明涉及使用（+）-α-（2,3-二甲氧基苯基）-1-[2-（4-氟苯基）乙基]-4-哌啶甲醇或其前药（II式）来治疗患有痴呆和多巴胺诱导的精神病症状的患者。